The ALPHAMEDIX-02 trial assessed 212Pb-DOTAMTATE in PRRT-naïve and PRRT-exposed GEP-NET patients, showing promising efficacy in both cohorts. PRRT-naïve patients exhibited a 60% response rate, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback